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Abstract
Introduction Fracture triggers a cascade of systemic and
local responses including inXammatory mediator signaling,
chemotaxis, osteogenic cell recruitment, diVerentiation and
proliferation at the fracture site. Early signaling between
immune cells and repair cells in fracture repair is not well
understood. Caveolin-1, a 21–24 kDa membrane protein
plays key roles in transmembrane signaling. This study was
to investigate the expression of caveolin-1 in human
peripheral blood mononuclear cells (PBMNCs) following
long bone fracture.
Methods PBMNCs were obtained from healthy volun-
teers or fracture patients at three time points following
fracture by density-gradient-centrifugation procedure.
Caveolin-1 gene expression and protein characterization
was examined by semi-quantitative RT-PCR, immunocyto-
chemistry and Western blot analysis.
Results Caveolin-1 mRNA and protein was expressed at
low levels in the PBMNCs of non-fracture samples. In con-
trast, caveolin-1 expression was greatly increased in the
PBMNCs of fracture patients 9–12 days and reduced at 16–
21 days following long bone fracture.
Conclusion The identiWcation of caveolin-1 in PBMNCs
and osteoblasts makes this cellular domain a new focus for
further investigation. We speculate that caveolin-1 expres-
sion in PBMNCs and osteoblasts play an important role in
signal transduction during the early stages of fracture heal-
ing and may be an indicator for normal or abnormal frac-
ture repair.
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Introduction
Caveolae are 50–100 nm membrane micro-invaginations
that are associated with a sub-compartment of the plasma
membrane in a wide variety of cells [29]. Four homologous
but distinct caveolin proteins have been deWned as caveo-
lin-1 and 1, 2 and 3, which have diVerent but overlapping
tissue distributions [23]. Caveolin-1 is the membrane pro-
tein that forms part of the caveolae [17]. Caveolin-1 mRNA
and protein expression is the highest in adipocytes, endo-
thelial cells, smooth muscle cells and Wbroblasts [10, 16].
Much like the Toll-like family of receptors involved in
innate immunity, the caveolin gene family is both structur-
ally and functionally conserved [14] suggesting an essential
role of caveolins in organizing and concentrating signaling
molecules.
The main functions of caveolae are transcytosis of both
large and small molecules across cell membrane [1]; signaling
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Arch Orthop Trauma Surgprocessing and transduction [6, 26]; sites of nitric oxide
(NO) production and endothelial nitric oxide synthase
(eNOS) [7, 8, 20, 28]. Diseases such as cancer [30], muscu-
lar dystrophy [24] and diabetes [13] appear to relegate to
the caveolae membrane system. Evidence for caveolin
expression in macrophages and peripheral blood mononu-
clear cells (PBMNCs) remains controversial, some groups
reporting the absence of caveolins in neuronal and blood
cells [5, 11], while others conWrmed the presence of caveo-
lin-1 in macrophages [9, 15] and dendritic cells [31]. A
recent report suggested that caveolin-1 expression could be
induced in blood cells during certain states of cell activa-
tion or by some stimuli [12].
Fracture repair is a complex physiological process
involving both local and systemic factors during which
bone shows a remarkable ability to mount a repair process
that not only restores the mechanical integrity but also ana-
tomical conWguration. Following the initial injury, there is
an accurate phase of hematoma formation and inXamma-
tion that may involve transient systemic responses such as
altered immune functions and systemic recruitment of
repair cells through circulation. It is well recognized that
failed initial inXammatory and immune response may result
in fracture non-union or delayed union. We hypothesized
that the immune responses lead to repair process may be
linked through the changes of expressions of caveolins. As
stated above, caveolins are the main signaling components
for various receptors in the cell membrane, and caveolin-1
may be an important cellular regulatory protein in cellular
signaling in various diseases situations [13, 24, 30] and
plays an important role in regulating fracture healing that
has never been discovered. Thus, the purpose of this study
is to exam caveolin-1 expression in PBMNCs at the mRNA
and the protein level in the patients having long bone frac-
ture and to compare that with healthy individuals.
Methods
Extraction of RNA from PBMNCs
About 15 ml of peripheral blood was taken from healthy
donors at one time point and from 7 patients with tibial or
femoral fracture at 3 time points following fracture, days 1–
3, 9–12 and 16–21. Patients were randomly selected, with
mean age of 31, and presented with no known metabolic
bone disease and were not under long-term medication. All
samples were taken with patient’s consent and local hospi-
tal’s ethical approval.
For isolating PBMNCs, 15 ml blood was Wrst diluted
twofold in sterile 0.9% saline, then two parts of the diluted
blood was layered over one part of Lymphoprep™
(Nycomeb Amersham, Oslo, Norway) and centrifuged at
500 g for 30 min at room temperature. The mononuclear
layer was aspirated, and washed twice in 10 ml of ice-cold
red cell lysis buVer (0.144 M NH4Cl, 1 mM NaHCO3) to
remove any remaining red cells. The mononuclear cells
were then washed twice in sterile saline solution, centri-
fuged at 600 g for 10 min at 4°C and the cell pellet lysed in
3 ml of guanidine isothiocyanate buVer with 1% -mercap-
toethanol and vortexed brieXy. RNA was isolated using the
phenol chloroform method outlined by Sacchi and Chom-
czynski [2]. RNA integrity was veriWed by ethidium bro-
mide staining of 28S and 18S ribosomal RNAs.
Preparation of human osteoblasts
Human bone-derived osteoblastic cells (HOB) were cul-
tured from trabecular bone explants obtained at the time of
total hip arthroplasty. The bone fragments were washed in
sterile saline to remove fat and blood cells. Small bone
chips (approximately 5 £ 5 £ 5 mm) were then placed in
T-75 Xasks, each containing 15 ml DMEM (Sigma, Pole,
UK) supplemented with 10% heat-inactivated fetal calf
serum (FCS), penicillin (100 U/ml), streptomycin (50 g/
ml) and amphotericin B (2.5 g/ml), and cultured at 37°C
in a 5% CO2 atmosphere. The Wrst medium change was
made at day 8 and thereafter the medium was changed
every Wve days until the Xask became conXuent around
weeks 4–5. All cells used in this study were between pas-
sages 2–4.
Cell staining and microscopy
Approximately 20% of the PBMNCs isolated from each
sample were spun onto glass slides by cytospin preparation
using a Cytospin 3 centrifugator (Shandon, USA). After
centrifugation, the slides were Wxed in 95% ethanol for
10 min and stored for future use. HOBs were harvested
from the Xasks by Trypsin/EDTA treatment, and the sepa-
rated cells were seeded in 4-well chamber slides (approxi-
mately 5 £ 104 cells/well) and cultured for 3 days. The
slides were then Wxed in 4% freshly prepared paraformade-
hyde for 10 min at room temperature and stored in PBS for
Immunocytochemical analysis.
For immunocytochemistry, the cell slides were washed
in PBS and incubated with 1% BSA in PBS for 10 min.
Mouse anti-human caveolin-1 antibody (Becton-Dickinson,
UK) diluted in PBS at a concentration of 5 g/ml was
applied to the slides and incubated for 1 h at room tempera-
ture. Following washing in PBS (3 £ 5 min), the slides
were then incubated with rabbit anti-mouse FITC conju-
gated secondary antibody for 45 min in a darkened cham-
ber. Slides were then washed in PBS (3 £ 5 min) to remove
the secondary antibody. To gain some visualization of the
nuclei some of the slides were incubated in 1.0 mg/ml123
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mounted in mounting media (50% PBS and 50% glycerol,
0.1% p-phenylenediamine, pH 8.0). Slides were viewed
under a Xuorescence microscope (Olympus, UK). Cells
were also examined using a non-Xuorescence disclosure
technique, where primary antibody was localized with the
horse radish peroxidase conjugated secondary antibody and
peroxidase substrate 3,3-di-amino-benzidine (DAB),
counterstained with hematoxylin and mounted.
Western blotting
PBMNCs were collected from three fracture patients at
three time-points following fracture and one time points
from three non-fracture controls. HOBs in culture were
used as positive controls. Cells were lysed by the addition
of RIPA lysis buVer (50 mM Tris-HCl, pH 7.4, 1% NP-40,
0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA,
1 mM PMSF, 1 mg/ml each of aprotinin, leupeptin, pepsta-
tin, 1 mM Na3VO4, 1 mM NaF) for 20 min on ice. Insolu-
ble materials were removed by centrifugation at
13,000 rpm for 10 min at 4°C. The supernatants were col-
lected and the protein concentrations determined using the
BCA protein estimation kit (Pierce, USA). An identical
amount of protein (10 g) from each lysate was subjected
to 10% sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE). Proteins were transferred to a
nitrocellulose Wlter and the Wlter blocked for 2 h in 5% non-
fat dried milk in TBS (50 mm Tris, 0.15 M NaCl pH 7.5)
containing 0.1% Tween-20, washed in TBS and incubated
at room temperature for 1 h in primary antibodies directed
against caveolin-1 (Becton Dickinson, UK). The nitrocellu-
lose membranes was then washed in TBS and incubated
with the appropriately labeled HRP-conjugated secondary
antibody. The enhanced chemiluminescence system (ECL,
Amersham, UK) was used for detection of protein bands.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Reverse transcriptase polymerase chain reaction (RT-PCR)
was performed for detecting caveolin-1 mRNA in the
PBMNC samples obtained. cDNA was produced using the
Wrst strand can synthesis kit (Roche, UK). Oligonucleotide
primers for caveolin-1 were synthesized according to the
available details on the human genome mapping project:
forward primer- TAC AAG CCC AAC AAC AAG; reverse
primer- ACA GTG AAG GTG GTG AAG for 35 cycles at
an annealing temperature of 60°C. Band analysis of PCR
products on agarose gels was conducted using the EDAS
120 software (Kodak Digital Science, UK). At least three
separate experiments were performed on each patient sam-
ple. RT-PCR was also performed on cDNA obtained from
human osteoblasts grown in culture. A housekeeping gene,
acidic ribosomal phosphoprotein (ARP), forward primer-
CGA CCT GGA AGT CCA ACT AC; reverse primer-
ATC TGC TGC ATC TGC TTG was also used.
Results
Immunocytochemistry of caveolin-1 in PBMNCs 
and HOBs
Almost all HOBs were strongly positive for caveolin-1,
staining was localized on the outer cell membrane with lit-
tle nuclear staining (Fig. 1a). There was no staining on the
negative control without primary antibody (Fig. 1b). In
PBMNCs, staining was particularly strong on the plasma
membrane and also in the cytoplasm (Fig. 1c). This may
correspond to soluble and insoluble forms of caveolin-1,
respectively. There was no diVerence in the immunostain-
ing pattern of caveolin-1 in the control blood cells and
those that were obtained from fracture patients (Fig. 1d).
Western blotting for caveolin-1
Caveolin-1 expression was not detected in the PBMNCs
from the controls, but was detectable in the PBMNCs of
patients with fracture (Fig. 2). The expression was weak in
the early time-point 1 (day 1–3 post fracture), peaked in the
middle time-point (day 9–12 post fracture) and declined at
later time point (day 16–21 post fracture) as shown in
Fig. 2.
RT-PCR of caveolin-1
RT-PCR results showed the level of caveolin-1 expression
varied in patients following fracture (Fig. 3a). Caveolin-1
was not readily or lowly expressed in non-fracture controls,
but the level of expression was dramatically increased in
patients following fracture and was particularly high in the
early stages of fracture healing (days 1–12). However, the
level of expression generally reduced around days 16–21
following fracture (Fig. 3a). There was no diVerence seen
on the expression ARP gene in all the samples (Fig. 3a).
HOBs were strongly positive for caveolin-1 gene expres-
sion (data not shown). Caveolin-1 gene expression was sig-
niWcantly increased in PBMNCs of fracture patients at days
9–12 (P = 0.018) than the control and other two time points
(Fig. 3b).
Discussion
The caveolins are increasingly implicated in diverse bio-
logical processes such as signal transduction, cellular123
Arch Orthop Trauma Surgtransport, cell diVerentiation and apoptosis [19–21, 25].
The presence of many receptors and signal transduction
molecules in caveolae suggests a key role for caveolae in
signal transduction [18].
A number of early investigators have shown the lack of
any caveolin isoforms in human peripheral blood cells. The
absence of caveolins was demonstrated in lymphocytes [5]
and platelets [4]. A recent report by Sengeløv et al. [27]
showed absence of the protein in neutrophils. Studies on
human blood cell lines, including the myeloid leukemic cell
line, erythroid cell lines [22], lymphoid cell lines [5], dem-
onstrated the absence of caveolin-1 in these cells, suggest-
ing the general lack of caveolin-1 in human blood cells.
However, Yan et al. [32] reported the presence of caveolin-
1 in neutrophils by Western blotting, and new research
indicated that some human T-cell lines express caveolin-1
as assessed by immunostaining and Western blotting [12].
Western blotting and RT-PCR results presented in the cur-
rent study would support the previous Wndings that caveo-
lin-1 is rare in non-fracture control mononuclear cells.
However, following a stimulus such as fracture, the
increased caveolin-1 gene expression supports the Wndings
of Hatanaka et al. [12] who suggested that the presence of
caveolin-1 in the PBMNCs in a disease stimulated state. In
the present study, caveolin-1 expression found in normal
mononuclear cells by ICC may represent a signiWcant Wnd-
ing that caveolin-1 may be a normal constituent of the
Fig. 1 a HOBs were strongly 
positive for caveolin-1, staining 
was localized on the outer cell 
membrane with little nuclear 
staining. b There was no staining 
on the control. c In PBMNCs, 
staining was particularly strong 
on the plasma membrane. d The 
pattern of the staining of caveo-
lin-1 using HRP immunostain-
ing method was similar to that 
seen in using Xuorescence 
immunostaining method
Fig. 2 Caveolin, a 22-kDa structural component of caveolae was pres-
ent in PBMNC lysates from fracture patients. Caveolin-1 expression
was not detected in the PBMNCs from the controls with no fracture
(Lane 1), but was detectable in the PBMNCs of patients following frac-
ture (Lanes 2–4). The expression was peaked in the middle time-point,
day 9–12 post fracture (Lane 3) and declined at later time points, day
16–21 post fracture (Lane 4)
Lane No. Sample
1 Control no fracture
2 Fracture patient time point 1
3 Fracture patient time point 2
4 Fracture patient time point 3
1 2 3 4
22 kDa123
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such as long bone fracture.
Caveolin-1 is highly expressed in terminally diVerenti-
ated mesenchymal stem cells (MSCs) including adipocytes,
endothelial cells, and smooth muscle cells. MSCs are also
known to be present in the blood of normal individuals [3,
33] and we cannot exclude the possibility that in long bone
fracture patients, the number of circulating MSCs is
increased. This was supported by the Wnding of Cilloni
et al. [3] who reported that bone surgery might act as a
stimulus for mobilization of MSCs in peripheral blood. The
increased expression of caveolin-1 in the PBMNCs of long
bone fracture patients at 9–12 days following fracture may
also indicate the increased presence of MSCs in circulation
in these patients. There is time-dependent change of caveo-
lin-1 expression during fracture repair: at early stage (1–
3 days after fracture) there is an acute hematoma formation
and caveolin-1 expression was low; at 9–12 days following
fracture, caveolin-1 expression in PBMNCs was greatly
increased and reached its peak and then its expression was
reduced at 16–21 days following fracture. The clinical sig-
niWcance of the current study is that it is for the Wrst time
we have documented the changes of caveolin-1 expression
during the cases of human long bone fracture healing. The
changes of pattern of caveolin-1 expression in PBMNCs
may indicate that during normal fracture healing, the acute
immune response phase should be within the Wrst 2 weeks,
and after that, the repair phase shall follow and caveolin-1
expression shall return to baseline level. If caveolin-1
expression in PBMNCs is prolonged, this may indicate a
delayed fracture healing and caveolin-1 expression in
PBMNCs may be used as a scanning tool for identifying the
patients with potential risk of fracture delayed or non-union
at the early stages of fracture (such as at 2 weeks following
fracture).
One of the limitations of the current study is that we did
not further isolate the subpopulations of cells in the
PBMNCs, therefore we were unable to tell which speciWc
cell type is responsible for caveolin-1 gene and protein up-
regulation. We were unable to examine the caveolin-1
expression in PBMNCs in patients with fracture non-union
or delayed union. Nonetheless, the present work forms a
foundation for further investigation. The future studies will
include the examinations of caveolin-1 expression in the
PBMNCs in fracture non-union or delayed patients and to
conWrm our hypothesis.
In conclusion, we found that human PBMNCs express
caveolin-1; the caveolin-1 gene and protein expression in
the PBMNCs is increased during the early stages of fracture
repair in the patients having long bone fracture in a time
dependent manner. The discovery of new signal transduc-
tion pathways such as caveolin-1 in PBMNCs may provide
an opportunity for understanding the complex interactions
that occur between immune responses and repair during
fracture repair and may be used as a scanning tool for pre-
dicting the risk of fracture delayed or non-union. Additional
studies will be necessary to fully evaluate the function of
caveolin-1 in circulating PBMNCs in fracture healing pro-
cess.
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